- Home
- PLRX vs ECOR Comparison
PLRX vs ECOR Comparison
Compare PLRX & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLRX | ECOR |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 85.6M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PLRX | ECOR |
|---|---|---|
| Price | $1.15 | $9.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $2.67 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 423.4K | 73.2K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.97 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $32,032,000.00 |
| Revenue This Year | N/A | $33.60 |
| Revenue Next Year | N/A | $30.40 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 27.20 |
| 52 Week Low | $1.02 | $4.41 |
| 52 Week High | $1.95 | $10.95 |
Technical Indicators
Market Signals| Indicator | PLRX | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 56.81 | 56.10 |
| Support Level | $1.12 | $5.59 |
| Resistance Level | $1.19 | $10.60 |
| Average True Range (ATR) | 0.04 | 0.63 |
| MACD | 0.00 | -0.11 |
| Stochastic Oscillator | 71.91 | 45.69 |
Price Performance
Historical ComparisonAbout PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
About ECOR electroCore Inc.
electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.